Setmelanotide
Setmelanotide is a peptide, indexed here under Melanocortin receptor peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Melanocortin receptor peptides |
| CAS registry number | 920014-72-8[1] |
| PubChem CID | 11993702[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C49H68N18O9S2[1] |
| Molecular weight | 1117.3 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Setmelanotide, development code RM-493, is a cyclic peptide described in the retrieved literature as a melanocortin-4 receptor agonist. The Drugs@FDA register returned an approved application under this generic name; that product is recorded in the regulatory status field and is not what this page describes. A 2021 Cell Research paper reports structures of active melanocortin-4 receptor complexes with NDP-alpha-MSH and setmelanotide, and a 2015 Journal of Clinical Endocrinology and Metabolism paper reports resting energy expenditure in obese individuals under RM-493.
The clinical records are in genetic obesity: a 2017 Molecular Metabolism evaluation in MC4R deficiency, a 2020 Lancet Diabetes and Endocrinology paper in severe obesity due to LEPR or POMC deficiency, 2020 Diabetes, Obesity and Metabolism and 2022 Lancet Diabetes and Endocrinology papers in Bardet-Biedl and Alstrom syndromes, a 2022 Journal of the Endocrine Society natural history study of POMC, PCSK1 and LEPR deficiency, a 2023 Orphanet Journal of Rare Diseases quality of life study, and a 2024 Lancet Diabetes and Endocrinology phase 2 trial in acquired hypothalamic obesity. A 2021 Drugs item records its first approval.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12]Reported mechanism
A melanocortin-4 receptor agonist, with the active receptor-Gs complex structure reported in the retrieved 2021 record.
[3, 5]Stated in the titles of the cited 2021 Cell Research and 2017 Molecular Metabolism papers.
Targets named in the cited records: melanocortin 4 receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA213793, marketed as IMCIVREE). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Setmelanotide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- RM-493
- Imcivree
- BIM-22493
Where this page sits
Research records
Cited research records for Setmelanotide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Bremelanotide — Melanocortin receptor peptides
- Melanotan II — Melanocortin receptor peptides
Named targets in the cited records
Class page: Melanocortin receptor peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Setmelanotide?
Setmelanotide, development code RM-493, is a cyclic peptide described in the retrieved literature as a melanocortin-4 receptor agonist. The Drugs@FDA register returned an approved application under this generic name; that product is recorded in the regulatory status field and is not what this page describes.
Which class is Setmelanotide indexed under?
Setmelanotide is indexed under Melanocortin receptor peptides. Melanocortin receptor peptides are analogues of alpha-melanocyte-stimulating hormone that act at melanocortin receptors.
What does the FDA application register show for Setmelanotide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA213793, marketed as IMCIVREE). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 11993702, Setmelanotide. PubChem, National Library of Medicine (2026). pubchem:11993702
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA213793. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:setmelanotide
- Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-α-MSH and setmelanotide. Cell research (2021). pmid:34561620
- RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. The Journal of clinical endocrinology and metabolism (2015). pmid:25675384
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Molecular metabolism (2017). pmid:29031731
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. The lancet. Diabetes & endocrinology (2020). pmid:33137293
- Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes, obesity & metabolism (2020). pmid:32627316
- Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. The lancet. Diabetes & endocrinology (2022). pmid:36356613
- Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide. Journal of the Endocrine Society (2022). pmid:35528826
- Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet journal of rare diseases (2023). pmid:36647077
- Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. The lancet. Diabetes & endocrinology (2024). pmid:38697184
- Setmelanotide: First Approval. Drugs (2021). pmid:33638809
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.